Resume

In the name of the Almighty
C.V. of Saleh Mohaghegh Hazrati, Ph.D.
ISTITUTION AND LOCATION DEGREE YEAR(s) FIELD OF STUDY
Tehran University, Tehran, IRAN B.Sc. 1977 Biology
Institute of Biochemistry & Biophysics, Tehran, IRAN M.Sc. 1983 Cell Biology
School of Public Health, Tehran University, Tehran MPH 1987 Master of Public Health
School of Public Health, Tehran Med. Sci. University Ph.D. 1993 Immunology

Research Activities (Papers, Presentations)

1. Kia SJ., Sahebjamee M., Mighani G., Mohaghegh hazrati S. ,Tohidast ekrad Z.,Vahedi M..The Impact of Immunotherapeutic G2 Vaccine on Treatment of Oral Lichen Planus. Shiraz Univ Dent J 2011; Vol.11, Supplement.
2. Khodaberdi Kalavi, and Saleh Mohaghegh Hazrati. Treatment of Chronic wounds: Time for Immunologic Concern on drug design? Accepted for publication.
3. JAFARZADEH A, HASSAN ZM, EBTEKAR M, MOHAGHEGH-HAZRATI S, AND TIRAIHI T. TIME-DEPENDENT CHANGES OF IMMUNOLOGIC RESPONSES AFTER BURN INJURY AND IMMUNOMODULATION BY CIMETIDINE AND PYRIMETHAMINE IN AN ANIMAL MODEL. Pak. J. Pharm. Sci., Vol.23, No.4, October 2010, pp.367-373.
4. Neamati A, Boskabady MH, Afshari JT, Hazrati SM, and Rohani A. The Effect of natural adjuvants on tracheal responsiveness and cell count in lung lavage of sensitized quinea pigs.Respirology 2009, 14, 877-884.
5. Kalavi K, Mordi AV, Keshtkar AA, Kalavi M, Namazi G & Mohaghegh Hazrati S. Diabetes foot Ulcers: A Novel treatment strategy. Iranian J Med Hypotheses and Ideas.
6. Latifynia A, Mohaghegh Hazrati S. Safety and toxicity of a new formulated Leishmania major preliminary vaccine in animal model Balb/c and small white conventional laboratory mice. Türkiye Parazitoloji Dergisi, 32 (2): XX – XX, 2008 Türkiye Parazitol Derg. Türkiye Parazitoloji Derneði, Turkish Society for Parasitology.
7. Neamati A, Boskabady MH, Tavakol Afshari J, Mohaghegh Hazrati S. The effect of the natural adjuvants on cell count in lung lavage of sensitized guinea pigs. Pharmacology online 2008;1:270-278.
8. Mohaghegh Hazrati S. Immunotherapy of Cancer with Th-1 activator (case report). The second international congress of cancer genetics: tumors of the upper body. 30Nov-2Dec 2006. http://iccg2006.tums.ac.ir/
9. Mohaghegh Hazrati S. Effect of Th-1 activators on treatment of adeno carcinoma of breast cancer in mice. The second international congress of cancer genetics: tumours of the upper body. 30Nov-2Dec 2006. http://iccg2006.tums.ac.ir/
10. Mohaghegh Hazrati S., Aghazadeh J., Mohtarami F, Abouzari M., Rashidi A. Immunotherapy of Prolactinoma with a T Helper 1 Activator Adjuvant and Autoantigens: A Case Report. Neuro-immuno-modulation 2006;13:205-208.
11. Mohaghegh Hazrati S. T helper Cell Activators (G2, PC, G2F) as Adjuvants (Biotherapy and prevention of Cancers and Allergies). New Approaches to Vaccine Development from the bench to the field. 8-10 September 2005, Berlin, Germany; pp26:90.
12. Jafarzadeh A, Khoshnoodi J, Ghorbani S, Mohaghegh Hazrati S, Faraj Mazaheri B, Shokri F. Differential Immunogenicity of a recombinant Hepatitis B vaccine in Iranian neonates: influence of ethnicity and environmental factors. I. J. I. 2004; 1 (2): 29-104.

13. Mohaghegh Hazrati S, Nasiri Khalaj S, Mohtarami F, Rahimi A. G2, PC and G2F in allergic asthma. Iranian J of Pediatrics 2004; 13 (2) suppl. 2 :30-31.
14. Mohaghegh Hazrati S , Nasiri Khalaj S , Mohtarami F. Vaccines Against Allergic Asthma. Third Iranian National Congress for Biotechnology, Sept. 2003.
15. Jafarzadeh A, Hassan ZA, Ebtekar M, Mohaghegh Hazrati S. Modulation of Cell- Mediated Immune Response Following Burn Injury in an Animal Model of Balb/c Mice. Journal of Rafsanjan University of Medical Sciences 2003;2:2; 94-101.
16. Mohaghegh Hazrati S. ,Mohtarami F. Combined non-specific Th-1 cells activator adjuvants and specific immunotherapy with auto-antigens of cancer. 3rd International Symposium on Genetic Anti-cancer Agents. Feb. 28-2 march, 2002, Amsterdam, The Netherlands .
17. Mohaghegh Hazrati S, et. al. Effect of Auto-antigens and Th-1 activator adjuvants on pituitary adenoma of prolactinoma. 6th International congress of endocrine disorders. Oct 5-9, 2001, Iranian J. of Endocrine and Metabolism, O-28, pp 22.
18. Mohaghegh Hazrati S, et al. Review of Immunotherapy with Th-1 activator and Auto-vaccines against cancers. Seminar on Diagnostic and new methods of Cancer treatment. June 6-8 2001, Babol University of Medical Sciences, IR of Iran.
19. Mohaghegh Hazrati S, et al. Immunotherapy of brain tumors and other cancers with immunopotent adjuvants and auto-antigens (case report). 23 April 2001, 11th International congress of Immunology, Sweden.
20. Mohaghegh Hazrati S & Mohtarami F. Why Th-1 activator vaccines could effective for Immunotherapy of chemical gas injured patients. The Role of Basic Sciences on defense against new wars. 12-13 March 2001 Tehran, University of Imam Hossein (A), IR of Iran.
21. Mohaghegh Hazrati S, Mohtarmai F, Ghoharani R, Pakrou M, Rohi D, Mohaghegh Hazrati F. Biotherapy of brain tumors and other cancers with immunopotent adjuvants and auto-antigens (case repot). The First North & North West Biotechnology Congress Islamic Republic of Iran. August 15-16, 2001, Urmia.
22. Latifynia A, Mohaghegh Hazrati S, Mohebali M. Pereperation of a new formulation of leihsmanial antigen and the evaluation of its effects on cell mediated induction in BALB/c and small white laboratory mice. The 9th Iranian congress on infectious diseases and tropical medicine 14 – 18 Jan. 2001, O24, pp20.
23. Mohaghegh Hazrati S, et al. The Role of GW-1, GM-1, PPD-A, PPD-B as immunopotent Adjuvants in cell Mediated Immune response against recombinant gp63 in BALB/c Mice. April 10-13, 2000, 9th International Congress on Infectious Diseases Buenos Aires, Argentina.
24. Mohaghegh Hazrati S, et al. Immunotherapy of pituitary Adenoma of Prolactinoma with Adjuvants (Cases Report). 17-19 May 2000, 5th Iranian congress of Immunology and Allergy, Tehran IR of Iran.
25. Baban B, Soubebielle B, Sharafi J, Mohaghegh Hazrati S and Safara M. Use of Mycobacterium vaccae (SRL 172) as an immunomodulating agent in association with Murine Melanoma Model B16-F10. Arch Razi Ins. 2000;51:4752.
26. Mohaghegh Hazrati S, et al. A novel an invasive and metastatic adenocarcinoma of breast cancer (HAZ-1) in small white laboratory mice. (Complementary Report). Sept. 6-9, 1999, The Fifth Biochemistry Congress of Uromia, IR of Iran.
27. Mohaghegh Hazrati S., et al. Biotherapy in Cancers, Asthma and Infectious and other diseases.. Nov 1999, First Azarbidjanian Congress on Biotechnology Uromia, IR of Iran.
28. Mohaghegh Hazrati S, Mohtarmai F, Ghoharani R, Pakrou M, Rohi D, Mohaghegh Hazrati F. Biotherapy of brain tumors and other cancers with immunopotent adjuvants and auto-antigens (case repot). The First North & North West Biotechnology Congress Islamic Republic of Iran. August 15-16, 2001, Urmia.
29. Mohaghegh Hazrati S, Mohtarami F, Ghoharani R, Pakrou M, Rohe D, Mohaghegh Hazrati F. Immunotherapy of brin tumors and other cancer with immunopetent adjunvants and auto- antigen (case report). 11th International congress of Immunology, 23-27 July 2001.
30. Mohaghegh Hazrati S, Hasumi KI, Sharfi J, Ali-Nedjad M, Khiri M, Ghadiri AA, Amani M, Mahbodi F, Mohtarami F, Djabbari H. The Role of GW-1, GM-1, PPD-A and PPD-B as immunopotent Adjuvants in Cell Mediated Immune Response against recombinant gp63 in BABL/c mice. 9th Internatioanl Congress on Infectious Diseases Buenos Aires, Argentina, April 10-13 2000. Abst. No 10808.
31. Sharafi J Mohaghegh Hazrati S. Immunotherapy in Cancer. The Fourth International Congress of Immunology & Allergry, Iran, Isfahan 13-15 May 1998.

32. Mohaghegh Hazrati S, Sharafi J, Kochmeshki R & Mohtarami F. Venous Ozone Therapy in Cancer. The Fourth International Congress of Immunology & Allergry, Iran, Isfahan 13-15 May 1998.
33. Eskandarpour M, Elahi E, Mohaghegh Hazrati S, Amir Moghaddam and Hasumi KI. The Study of CD44 Variant Isoforms in Different Tumors. UICC Symposium, Familial Cancer and Prevention, Molecular Epidemiology. May 14-16 1997, Kobe Japan. (Presentation).
34. Mohagheh Hazrati S, Rabani, Mohebeali M, Eslami MB. Evaluation of vaccination against Tetanous Toxoid within Defense Army during Iraq and Iran War. The First Seminar of Infectious Diseases in War and Unexpected events. Bagiyatalah Medical Sience University; 21-23 Oct 1997: p21.
35. Mahmodzadeh A, Mohaghegh Hazrati S, Sobati R & Mohtarami M. Evaluation of Leishmanization after Stopping this Method of Control of Leishmaniasis in Islamic Rep. of Iran. XIV International Congress for Tropical medicine and Malaria, Nov. 17-22, 1996, Nagasaki, Japan , O-34-4.
36. Mohaghegh Hazrati S. The Function of Viruses in water and their treatment. The National Congress on Environmental Health 1996. (Presentation).
37. Mohaghegh Hazrati S, Valizadeh M, Shojaei S. Establishing Macrophage culture for evaluation Itraconazole and Ketakonazole against leishmaniasis parasites (In vitro model) . May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
38. Mohaghegh Hazrati S. Controversial role of BCG on treatment of cancers. First Seminar of Immunotherapy of cancer. Tehran Medical Sciences University Dec 1995. (Presentation)
39. Mohaghegh Hazrati S. Immunoregulation of Antibody Synthesis in Sjogren’s Syndrome. May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
40. Mohaghegh Hazrati S, Majidi J & Zahir Mohammed-Hassan. Effect of BCG on Leishmanization within the mice. May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
41. Mohaghegh Hazrati S, Valizadeh M, Shojaei S. In vitro effect of intaconazole and keteconazol on L. major infected mouse macrophages. May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
42. Mohaghegh Hazrati S. Immunoregulation of Antibody Synthesis in Sjogren’s Syndrome. May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
43. Mohaghegh Hazrati S. Mohebali M, Latifinia A. Preparation of vaccine against cutaneous leishmaniasis (Phse I). May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
44. Sharafi J, Mohaghgh Hazrati S, Hasumi KI. Combined surgery, chemo, Radio- Immunotherapy of cancers. May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
45. Mohaghegh Hazrati S, Valizadeh M. NNN Modified Medium for prolonged and mass cultivationg of Leishmania promastigotes (SPH media and HVMA 273). May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
46. Mohaghegh Hazrati S, Pezeshki M, Khodadadi A. Evaluation of vaccination against Tetanus within the pregnant women under PHC and Hospital Helath Cared System. May 1995, 8th International Congress of Geographic Medicine, (Infectious Diseases), Shiraz University of Medical Sciences, Shiraz, Iran. (Presentation).
47. Baban B, Soubebielle B, Sharafi J, Mohaghegh Hazrati S and Safara M. Use of Mycobacterium vaccae (SRL 172) as an immunomodulating agent in association with Murine Melanoma Model B16-F10. Arch Razi Ins. 2000;51:4752.
48. Eskandarpour M, Elahi E, Mohaghegh Hazrati S & Moghaddam A. A study of CD44 variant isoforms in esophagus and stomach cancers. Iranian Academic Association , Second Annual Congerence Proceedings (Science and Technology in Medicine and Engineering) , 1997; 1:43-59.

49. Mahmoodzadeh A, Mohaghegh Hazrati S, Sobaty H, Faghizadeh S. Evaluation of Leishmanization in the military Forces. Kowsar Medical Journal 1997; 2:4. (Parsian paper).
50. Mohaghegh Hazrati S, Sharafi J & Kochmeshki R. Venous Ozone Therapy in Cancer and Other Diseases 1996 (One Vol. ; 1-56).
51. Adam S Hay, Thor G Theander, Lars Hviid, Saleh Mohaghegh Hazrati, Micheal Kemp and Arsalan Kharazmi. The major surface glycoprotein (gp63) from Leishmania major and Leishmania and Leishmania donovni cleaves CD4 molecules on human T cells. J Immunol 1994; 152: 4542-4548.
52. Mohebali M, Mohaghegh Hazrati S. Evaluation of the effectiveness of leishmanization in Revolutionary Guards of the Islamic Republic of Iran. Paper presented at the National Seminar on Leishmaniasis, Teheran, 1990 (in Farsi).

Memberships;
1. Member of European Tissue Culturs Society
2. British Society for Cell Biology
3. The American Society for Cell Biology
4. Iranian Society for Immunology and Allergy
5. Iranian Society for Biotechnology
6. West Azarbidjan Society for Biotechnology
7. Iranian Society for Asthma & Allergy
8. International Society for Infectious Diseases PROFESSIONAL EXPERIENCE

1974-1978 Laboratory Instructor, Department of Biochemistry, IRAN Pasteur Institute,
1978-1984 Pathobiologist, (Department of Pathobiology of School of Public Health, Tehran Medical Sciences University
1984-1993 Assistant Lecturer, School of Public Health and Institute of Public Health Researches, Tehran Medical Science University, IR of IRAN
!991-1992 Vice president of Basic and Health Sciences Committee of Ministry of Health, Treatment and Education
1993- Count. Lecturer in Field of Immunology, Teaching for B.Sc., M.Sc. and Ph.D. Students.
1995- 2007 Dean of Euromieh Training and Research Health Center,
1993- Count Supervising of different M.Sc. & Ph.D. Thesis’s 1999-2001 President of West Azerbaijan Biotechnology Society. 2002- 2004. President of Iranian Biotechnology Society,(Website: http://ibs.nrcgeb.ac.ir)
1993 – Count. Head of Different Research Projects.
2003 –2005 Head of Incubators Center of Biotechnology and Herbal Plants of West Azerbaijan State of IR of IRAN.
1999-2002 Head of Park of Biotechnology In West Azerbaijan State of IR of IRAN Project. 2002-2006. Member of Herbal Medicine Committee of Minstary of Health, Treatment and
Education.
2002-2006t. Member of UNEP-GEF Project of National Biosafety Frameworks (Department of Environment I.R. IRAN.
2001-2005. Member of Recycle Committee Of West Azarbidjan.
2000- Count. Reviewer of Iranian Biomedical Journal (Institute Pastor of IRAN)
2005-Count. Regional Editors of Ansi-Biotechnology and Molecular Sciences Journal. 2005- 2006. National Biosafety Framework: the National Coordinating Committee
member.
Inoviations;
1. G2 Vaccine as a cell mediated activator registered in the Iranian Patent office on 2007.
2. PC Vaccine as a cell mediated activator registered in the Iranian Patent office on 2007.
3. G2F Vaccine as a cell mediated activator registered in the Iranian Patent office on 2007.